Alkermes' Alixorexton Shows Positive Results in Phase 2 Study for Narcolepsy Type 1
Alkermes plc announced the publication of data from its Vibrance-1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton, an investigational oral, selective orexin 2 receptor (OX2R) agonist, demonstrated statistically significant and clinically meaningful improvements in wakefulness and cataplexy. The study, involving 92 adults with NT1, showed that once-daily alixorexton led to improvements in objective and subjective measures of excessive daytime sleepiness, as assessed by the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS). All tested dose groups (4 mg, 6 mg, and 8 mg) achieved mean sleep latency values within the normative range. Additionally, the 6 mg alixorexton group experienced a significant decrease in weekly cataplexy rate. The drug was generally well tolerated, with most treatment-emergent adverse events being mild to moderate in severity and no serious adverse events reported. These positive results have led Alkermes to... 
